PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Assumptions • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Disease overview • Understanding osteoarthritis • Etiology and pathophysiology • Risk factors • Signs and symptoms • Diagnosis • Disease management • Surgical treatment • Epidemiology • Economic burden of osteoarthritis PART 06: Pipeline portfolio • Information on pipeline candidates • Ampion • Tanezumab • Zilretta (FX006) • Fasinumab • IP 880 • SoluMatrix Naproxen • ABT-981 • AF-219 • ASP7962 PART 07: Osteoarthritis pain drugs: Clinical trials PART 08: Opportunities for research in osteoarthritis • Gaps between current research and possible research issues • Challenges for vendors involved in osteoarthritis drug development PART 09: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 10: Market segmentation by drug class • NSAIDs • Opioids • Viscosupplements • Corticosteroids • Others • Global NSAIDs market • Global opioids market • Global viscosupplements market • Global corticosteroids market PART 11: Market segmentation by ROA • Oral • Parenteral • Topical PART 12: Market segmentation by dosage form • Solid • Liquid • Semi-solid PART 13: Geographical segmentation • Osteoarthritis pain drugs market in Americas • Osteoarthritis pain drugs market in US • Osteoarthritis pain drugs market in EMEA • Osteoarthritis pain drugs market in APAC PART 14: Market drivers • Significant unmet medical needs • Promising drug pipeline • Increase in prevalence of osteoarthritis and obesity PART 15: Impact of drivers PART 16: Market challenges • Preference for alternative therapies • Loss of patent exclusivity of branded therapies • Adverse effects of drugs PART 17: Impact of drivers and challenges PART 18: Market trends • Emergence of new treatments • Use of off-label drugs • Strategic alliances PART 19: Vendor landscape • Competitive scenario • Abbott Laboratories • Johnson & Johnson • Novartis • Pfizer • Other prominent vendors PART 20: Upcoming vendors with novel approaches • Ampio Pharmaceuticals • Flexion Therapeutics • Kitov Pharmaceuticals PART 21: Appendix • List of abbreviations PART 22: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria Exhibit 03: Types of osteoarthritis Exhibit 04: Etiology and pathophysiology of osteoarthritis Exhibit 05: Signs and symptoms of osteoarthritis Exhibit 06: Diagnostic test for osteoarthritis Exhibit 07: Treatment options for osteoarthritis Exhibit 08: Non-pharmacological therapies used for osteoarthritis Exhibit 09: Pharmacotherapy therapy for osteoarthritis Exhibit 10: Surgical treatment Exhibit 11: Economic burden of osteoarthritis Exhibit 12: Distribution of direct costs of osteoarthritis Exhibit 13: Cost analysis of treatment for individuals with osteoarthritis Exhibit 14: Pipeline molecules for osteoarthritis pain Exhibit 15: Osteoarthritis clinical trials by development phase Exhibit 16: Share of Phase I, II, and III pipeline candidates in osteoarthritis pain drugs market Exhibit 17: Osteoarthritis clinical trials by trial status Exhibit 18: Highlights of osteoarthritis research opportunities: Exhibit 19: Global osteoarthritis pain drugs market 2015-2020 ($ billions) Exhibit 20: Current opportunities of osteoarthritis industry Exhibit 21: Five forces analysis Exhibit 22: Global osteoarthritis pain drugs market segmentation by drug class Exhibit 23: Some NSAIDs used to treat osteoarthritis pain Exhibit 24: Global osteoarthritis pain drugs market shares by drug class 2015 Exhibit 25: Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 ($ billions) Exhibit 26: Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 percentage) Exhibit 27: Global osteoarthritis pain drugs market 2015-2020 Exhibit 28: YoY growth rate of global osteoarthritis pain drugs market segments 2015-2020 Exhibit 29: Global NSAIDs market 2015-2020 ($ billions) Exhibit 30: Global opioids market 2015-2020 ($ billions) Exhibit 31: Global viscosupplements market 2015-2020 ($ billions) Exhibit 32: Global corticosteroids market 2015-2020 ($ billions) Exhibit 33: Global osteoarthritis pain drugs market segmentation by ROA Exhibit 34: Global osteoarthritis pain drugs market segmentation by ROA 2015 Exhibit 35: Global osteoarthritis pain drugs market segmentation by dosage form Exhibit 36: Global osteoarthritis pain drugs market segmentation by ROA 2015 Exhibit 37: Global osteoarthritis pain drugs market by geographical segmentation 2015 Exhibit 38: Global osteoarthritis pain drugs market revenue by geography 2015-2020 ($ billions) Exhibit 39: Global osteoarthritis pain drugs market revenue by geography 2015-2020 Exhibit 40: Global osteoarthritis pain drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions) Exhibit 41: Osteoarthritis pain drugs market in Americas 2015-2020 ($ billions) Exhibit 42: Osteoarthritis pain drugs market in Americas 2015 Exhibit 43: Osteoarthritis pain drugs market in US 2015-2020 ($ billions) Exhibit 44: Osteoarthritis pain drugs market in EMEA 2015-2020 ($ billions) Exhibit 45: Osteoarthritis pain drugs market in APAC 2015-2020 ($ billions) Exhibit 46: Unmet medical needs with current osteoarthritis pain treatments Exhibit 47: Prevalence of osteoarthritis in 2012 and 2022 (millions) Exhibit 48: Average annual prevalence of osteoarthritis in US Exhibit 49: Incidence of osteoarthritis in overweight and normal weight individuals 2013 Exhibit 50: Worldwide estimated osteoarthritis population growth 2010-2020 Exhibit 51: Population aged 60 years and over: World, developed, and developing regions (millions) Exhibit 52: Expected growth of older population in US 2010-2050 Exhibit 53: Impact of drivers Exhibit 54: Alternative therapies for osteoarthritis pain Exhibit 55: Use of CAM therapies among individuals in US Exhibit 56: Impact of drivers and challenges Exhibit 57: Future therapeutics in osteoarthritis pain treatment Exhibit 58: Key takeaways Exhibit 59: Key takeaways Exhibit 60: Novartis: YoY revenue and growth rate of Voltaren 2013-2015 ($ millions) Exhibit 61: Key takeaways Exhibit 62: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ millions) Exhibit 63: Pfizer: Geographical segmentation of Celebrex 2015 Exhibit 64: Key takeaways Exhibit 65: Flexion Therapeutics: Pipeline products Exhibit 66: Kitov Pharmaceuticals: Pipeline products Exhibit 67: Osteoarthritis pain market size model

Abbott Laboratories, Johnson & Johnson, Novartis International, Pfizer, AbbVie, Abiogen Pharma, Afferent Pharmaceuticals, Astellas Pharma, BioDelivery Sciences International, CrystalGenomics, Cytori Therapeutics, Daiichi Sankyo, Eli Lilly, Endo Pharmaceuticals Holdings, Horizon Pharma, iCeutica, Iroko Pharmaceuticals, Merck, Nuvo Research, Regeneron Pharmaceuticals, Sanofi, SantoSolve, Techfields Pharma, Winston Pharmaceuticals, Yooyoung Pharmaceutical, Zynerba Pharmaceuticals.